Salarius Pharmaceuticals, Inc. (SLRX)
Largest Insider Buys in Sector
SLRX Stock Price History Chart
SLRX Stock Performance
About Salarius Pharmaceuticals, Inc.
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
Insider Activity of Salarius Pharmaceuticals, Inc.
Over the last 12 months, insiders at Salarius Pharmaceuticals, Inc. have bought $0 and sold $0 worth of Salarius Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Salarius Pharmaceuticals, Inc. have bought $71,551 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 37,500 shares for transaction amount of $7,016 was made by Lieber Jonathan I () on 2022‑06‑07.
List of Insider Buy and Sell Transactions, Salarius Pharmaceuticals, Inc.
| 2022-06-07 | Lieber Jonathan I | 37,500 0.0703% | $0.19 | $7,016 | -53.27% | |||
| 2022-06-07 | Burleson Tess | 27,700 0.0499% | $0.18 | $4,986 | -53.27% | |||
| 2022-06-06 | McVicar William K. | 26,553 0.0492% | $0.19 | $5,000 | -53.68% | |||
| 2022-06-03 | HANISH ARNOLD C | 28,000 0.0521% | $0.18 | $5,152 | -52.08% | |||
| 2022-05-31 | Rosenblum Mark J | Exec VP Finance, CFO | 28,000 0.0522% | $0.18 | $5,040 | -50.75% | ||
| 2022-05-26 | Arthur David J. | Chief Executive Officer | 10,800 0.0206% | $0.18 | $1,990 | -50.53% | ||
| 2022-03-03 | Arthur David J. | Chief Executive Officer | 139,488 0.3016% | $0.39 | $54,540 | -51.33% | ||
| 2022-03-03 | Rosenblum Mark J | Exec VP Finance, CFO | 76,246 0.1648% | $0.39 | $29,812 | -51.33% | ||
| 2021-08-17 | Arthur David J. | Chief Executive Officer | 4,000 0.0091% | $0.90 | $3,582 | -49.84% | ||
| 2021-08-10 | HANISH ARNOLD C | director | 7,000 0.0156% | $0.88 | $6,167 | -48.23% | ||
| 2020-08-21 | HANISH ARNOLD C | director | 4,000 0.0226% | $0.98 | $3,920 | +10.72% | ||
| 2020-08-19 | Arthur David J. | Chief Executive Officer | 2,000 0.011% | $1.01 | $2,020 | +4.41% | ||
| 2020-08-17 | Rosenblum Mark J | Exec VP Finance, CFO | 5,000 0.0282% | $1.00 | $5,000 | +7.79% | ||
| 2020-02-19 | Rosenblum Mark J | Exec VP Finance, CFO | 2,000 0.0208% | $0.95 | $1,900 | -5.19% | ||
| 2020-02-18 | Jordan Scott | Chief Business Officer | 11,300 0.1185% | $0.90 | $10,170 | +1.11% | ||
| 2020-02-13 | Rosenblum Mark J | Exec VP Finance, CFO | 5,000 0.0506% | $0.86 | $4,295 | +0.72% | ||
| 2020-02-11 | Northrup Jonathan P | director | 8,700 0.1255% | $1.15 | $10,005 | +6.95% | ||
| 2020-02-11 | Arthur David J. | Chief Executive Officer | 2,175 0.0314% | $1.15 | $2,501 | +6.95% | ||
| 2020-02-11 | McVicar William K. | director | 8,700 0.1255% | $1.15 | $10,005 | +6.95% | ||
| 2020-02-11 | McCreedy Bruce J Jr. | director | 8,700 0.1255% | $1.15 | $10,005 | +6.95% |
Insider Historical Profitability
| Boston Foundation, Inc. | 10 percent owner | 1600000 40.6253% | $2.48 | 0 | 2 | |
| MacKinnon Roderick | director | 431277 10.9505% | $2.48 | 1 | 0 | |
| Northrup Jonathan P | director | 352713 8.9557% | $2.48 | 1 | 0 | +6.95% |
| Arthur David J. | Chief Executive Officer | 303574 7.708% | $2.48 | 5 | 0 | <0.0001% |
| Rosenblum Mark J | Exec VP Finance, CFO | 148319 3.7659% | $2.48 | 5 | 0 | <0.0001% |
| Wessel Thomas | Chief Medical Officer | 57064 1.4489% | $2.48 | 2 | 0 | |
| HANISH ARNOLD C | 46350 1.1769% | $2.48 | 5 | 0 | <0.0001% | |
| Lieber Jonathan I | 37500 0.9522% | $2.48 | 1 | 0 | <0.0001% | |
| Burleson Tess | 32050 0.8138% | $2.48 | 2 | 0 | <0.0001% | |
| Jordan Scott | Chief Business Officer | 31609 0.8026% | $2.48 | 1 | 0 | +1.11% |
| McVicar William K. | 26553 0.6742% | $2.48 | 2 | 0 | <0.0001% | |
| McCreedy Bruce J Jr. | director | 8700 0.2209% | $2.48 | 1 | 0 | +6.95% |
| SCULLEY JOHN | director | 4709 0.1196% | $2.48 | 2 | 0 | |
| KOZIN MARC D | director | 4500 0.1143% | $2.48 | 1 | 0 | |
| Stacy Michelle | director | 2585 0.0656% | $2.48 | 1 | 0 | |
| McCabe John P. | VP of Finance & Treasurer | 1650 0.0419% | $2.48 | 1 | 0 | |
| Westphal Christoph H | 10 percent owner | 0 0% | $2.48 | 80 | 1 | |
| Longwood Fund II, L.P. | 10 percent owner | 0 0% | $2.48 | 2 | 1 |
Institutional Investor Ownership
| Armistice Capital Llc | $44,402.00 | 1.76 | 84,000 | -4.54% | -$2,114.38 | <0.01 | |
| Horizon Kinetics LLC | $16,436.00 | 0.65 | 31,094 | 0% | +$0 | <0.0001 | |
| Renaissance Technologies | $15,000.00 | 0.59 | 28,242 | +6.81% | +$956.02 | <0.0001 | |
| Geode Capital Management | $13,093.00 | 0.52 | 24,771 | 0% | +$0 | <0.0001 | |
| The Vanguard Group | $7,698.00 | 0.31 | 14,563 | 0% | +$0 | <0.0001 | |
| Tower Research Capital | $4,455.00 | 0.18 | 8,422 | +2.95% | +$127.48 | <0.0001 | |
| Advisor Group Holdings Inc | $733.00 | 0.03 | 1,387 | 0% | +$0 | <0.0001 | |
| Morgan Stanley | $32.00 | <0.01 | 60 | 0% | +$0 | <0.0001 | |
| Wells Fargo | $16.00 | <0.01 | 31 | +3.33% | +$0.52 | <0.0001 | |
| Fidelity Investments | $4.00 | <0.01 | 7 | -78.79% | -$14.86 | <0.0001 | |
| Bank of America | $8.00 | <0.01 | 16 | 0% | +$0 | <0.0001 | |
| UBS | $10.00 | <0.01 | 18 | -76.92% | -$33.33 | <0.0001 | |
| BlackRock | $8.00 | <0.01 | 15 | -68.08% | -$17.07 | <0.0001 |